{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TARGET&page=15", "query": { "intervention": "TARGET", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 9976, "total_pages": 998, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TARGET&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TARGET&page=14&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T09:09:53.492Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03805360", "title": "The Erector Spinae Plane Block and Its Effect on Respiratory Status and Pain Management in Rib Fracture Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rib Fractures" ], "interventions": [ { "name": "Ropivacaine", "type": "DRUG" }, { "name": "Normal Saline Flush, 0.9% Injectable Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2019-05-24", "completion_date": "2020-01-10", "has_results": false, "last_update_posted_date": "2020-08-07", "last_synced_at": "2026-10-31T09:09:53.492Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03805360" }, { "nct_id": "NCT00712582", "title": "Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Etoposide, carboplatin, ifosfamide", "type": "DRUG" }, { "name": "Rituximab, Ifosfamide, Etoposide, Carboplatin", "type": "DRUG" }, { "name": "Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 96, "start_date": "2008-07-01", "completion_date": "2021-03-12", "has_results": true, "last_update_posted_date": "2022-06-21", "last_synced_at": "2026-10-31T09:09:53.492Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00712582" }, { "nct_id": "NCT02012959", "title": "Study of the Safety and Effectiveness of SAMSCA® (Tolvaptan) in Children and Adolescents With Euvolemic or Hypervolemic Hyponatremia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hyponatremia" ], "interventions": [ { "name": "Tolvaptan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Weeks", "maximum_age": "17 Years", "sex": "ALL", "summary": "4 Weeks to 17 Years" }, "enrollment_count": 9, "start_date": "2015-09-22", "completion_date": "2017-07-24", "has_results": true, "last_update_posted_date": "2018-09-26", "last_synced_at": "2026-10-31T09:09:53.492Z", "location_count": 5, "location_summary": "Aurora, Colorado • Washington D.C., District of Columbia • New York, New York + 2 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "New York", "state": "New York" }, { "city": "Richmond", "state": "Virginia" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02012959" }, { "nct_id": "NCT06447662", "title": "A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Pancreatic Ductal", "Colorectal Neoplasms", "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "PF-07934040", "type": "DRUG" }, { "name": "Gemcitabine", "type": "COMBINATION_PRODUCT" }, { "name": "Nab-paclitaxel", "type": "COMBINATION_PRODUCT" }, { "name": "Cetuximab", "type": "COMBINATION_PRODUCT" }, { "name": "Fluorouracil", "type": "COMBINATION_PRODUCT" }, { "name": "Oxaliplatin", "type": "COMBINATION_PRODUCT" }, { "name": "Leucovorin", "type": "COMBINATION_PRODUCT" }, { "name": "Bevacizumab", "type": "COMBINATION_PRODUCT" }, { "name": "Pembrolizumab", "type": "COMBINATION_PRODUCT" }, { "name": "pemetrexed", "type": "COMBINATION_PRODUCT" }, { "name": "Cisplatin", "type": "COMBINATION_PRODUCT" }, { "name": "Paclitaxel", "type": "COMBINATION_PRODUCT" }, { "name": "Carboplatin", "type": "COMBINATION_PRODUCT" }, { "name": "Sasanlimab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2024-06-27", "completion_date": "2026-10-09", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-31T09:09:53.492Z", "location_count": 26, "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 14 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06447662" }, { "nct_id": "NCT07335562", "title": "A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Systemic Sclerosis" ], "interventions": [ { "name": "BMS-986353", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Nintedanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Juno Therapeutics, Inc., a Bristol-Myers Squibb Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 92, "start_date": "2027-02-03", "completion_date": "2030-11-11", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-31T09:09:53.492Z", "location_count": 17, "location_summary": "Scottsdale, Arizona • Aurora, Colorado • Denver, Colorado + 14 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07335562" }, { "nct_id": "NCT03634579", "title": "MRI Guided Prostate Cancer Focal Laser Ablation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "MRI Guided Focal Laser Interstitial Thermal Ablation", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 9, "start_date": "2018-06-01", "completion_date": "2019-03-15", "has_results": true, "last_update_posted_date": "2020-03-23", "last_synced_at": "2026-10-31T09:09:53.492Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03634579" }, { "nct_id": "NCT00003127", "title": "S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Cancer" ], "interventions": [ { "name": "amifostine trihydrate", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "FEMALE", "summary": "16 Years and older · Female only" }, "enrollment_count": 57, "start_date": "1998-02", "completion_date": "2004-07", "has_results": false, "last_update_posted_date": "2012-06-14", "last_synced_at": "2026-10-31T09:09:53.492Z", "location_count": 94, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 62 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003127" }, { "nct_id": "NCT06566703", "title": "Testing ANSOS for Efficacy in Multi-Tribal Urban Communities", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Smokeless Tobacco Cessation" ], "interventions": [ { "name": "All Nations Snuff Out Smokeless", "type": "BEHAVIORAL" }, { "name": "Healthy Living", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Lehigh University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 384, "start_date": "2023-08-18", "completion_date": "2028-10-31", "has_results": false, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-10-31T09:09:53.492Z", "location_count": 1, "location_summary": "Bethlehem, Pennsylvania", "locations": [ { "city": "Bethlehem", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06566703" }, { "nct_id": "NCT07380256", "title": "Visual Influences on Vestibular Adaptation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Vestibular Hypofunction", "Binocular Vision Abnormalities", "Reduced Vision" ], "interventions": [ { "name": "StableEyes: Incremental Vestibulo-Ocular Reflex Adaptation (IVA)", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 100, "start_date": "2026-02-04", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-10-31T09:09:53.492Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07380256" }, { "nct_id": "NCT01009346", "title": "RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "RAD001", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2009-10", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2018-07-17", "last_synced_at": "2026-10-31T09:09:53.492Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01009346" } ] }